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Natural killer (NK) cells have antitumor, antiviral, and
antibacterial functions, and efforts are being made to
manipulate them in immunotherapeutic approaches.
However, their activation mechanisms remain poorly
defined, particularly during bacterial infections. Here,
we show that upon lipopolysaccharide or E. coli
exposure, dendritic cells (DCs) produce three cyto-
kines—interleukin 2 (IL-2), IL-18, and interferon b
(IFN-b)—necessary and sufficient for NK cell activa-
tion. IFN-b enhances NK cell activation by inducing
IL-15 and IL-15 receptor a not only in DCs but, sur-
prisingly, also in NK cells. This process allows the
transfer of IL-15 on NK cell surface and its cis presen-
tation. cis-presented NK cell-derived and trans-
presented DC-derived IL-15 contribute equally to
optimal NK cell activation.INTRODUCTION
Natural killer (NK) cells are lymphocytes of innate immunity
equipped only with germline-encoded receptors not undergoing
somatic rearrangement. Most of them are specifically designed
to monitor major histocompatibility complex (MHC) and MHC-
like molecules on host cells, promptly detecting stressful alter-
ations, usually due to viral infection or transformation (Horowitz
et al., 2012). Upon recognition of abnormal cells, NK cells release
the content of cytolytic granules, leading to the death of target
cells.
Cytotoxicity in antiviral and antitumor responses is the tradi-
tionally acknowledged contribution of NK cells to immunity, but
it is by no means the only one. NK cells are also powerful pro-
ducers of proinflammatory cytokines, particularly interferon g
(IFN-g), of which NK cells are the earliest source in several typesCell Reof infections (Horowitz et al., 2012; Martı´n-Fontecha et al., 2004).
IFN-g potently activates macrophages and favors Th1 lineage
commitment of CD4+ T cells. As such, it comes as no surprise
that early IFN-g release by NK cells is crucial to control a variety
of infections by intracellular (such as Listeria monocytogenes)
and extracellular (such as Escherichia coli) bacteria while adap-
tive immunity is being primed (Dunn and North, 1991; Ferlazzo
et al., 2003; Lapaque et al., 2009; Newman and Riley, 2007; Pon-
tiroli et al., 2012). This raises the question of how NK cells are
alerted by the presence of bacteria, as NK cells are classically
thought not to bear any receptor-recognizing bacterial products.
In principle, detection of intracellular bacteria by NK cells might
still be possible through their well-known patrolling mechanism,
which seeks stress-related alterations in host cells. However,
recognition of extracellular bacteria is harder to envision.
Recently, two important lines of research have uncovered impor-
tant aspects of NK cell biology that might shed light on this topic.
First, both mouse and human NK cells express Toll-like recep-
tors (TLRs) (Lauzon et al., 2007), which recognize molecular pat-
terns associated to pathogens (PAMPs) (Medzhitov et al., 1997),
and second, accessory cells, such as dendritic cells (DCs), are
able to sense the presence of pathogens and, in turn, activate
NK cells, thus virtually expanding NK cell recognition capabilities
(Fernandez et al., 1999; Newman and Riley, 2007).
The contribution of autonomous pathogen recognition by NK
cells through TLRs is debated, with some works showing
enhanced effector functions (Lauzon et al., 2006; Pisegna
et al., 2004; Schmidt et al., 2004; Sivori et al., 2004) upon stimu-
lation of NK cell TLRs, whereas others report no impact (Gorski
et al., 2006; McCartney et al., 2009; Newman and Riley, 2007).
To reconcile those discordant data, some authors proposed
that the role of NK cell TLRs might become apparent only in syn-
ergism with accessory cell-derived cytokines (Lauzon et al.,
2007; Sivori et al., 2004). By contrast, the role of accessory cells
in NK cell activation is better appreciated. In 1999, a pioneering
work by Fernandez et al. (1999) formally demonstrated that DCs
are able to activate NK cells via the joint contribution of bothports 4, 1235–1249, September 26, 2013 ª2013 The Authors 1235
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Figure 1. DCs Are Required for NK Cell Activation
(A) Activated (IFN-g-positive) NK cells, defined as CD49b+ CD3, analyzed by
intracellular staining at the indicated time points in the draining lymph node
after LPS s.c. injection.
(B) Activated (IFN-g-positive) NK cells in CD11c.DOG mice before (-) and 5 hr
after LPS injection. Where indicated, mice were pretreated for 4 hr with DT to
eliminate DCs.
n R 3. Error bars depict SEM. Statistical significance was determined with a
two-tail t test. *, p < 0.05.
See also Figure S1.contact-dependent and contact-independent mechanisms. This
observation has been repeatedly confirmed in a variety of exper-
imental settings. Yet there is little agreement about the mecha-
nism through which DCs activate NK cells (Ferlazzo et al.,
2002; Newman and Riley, 2007).
Moreover, confusion can arise from the finding that accessory
cells may not only activate NK cells—resulting in immediate
effects, such as cytokine production at the site of interaction—
but also ‘‘prime’’ them by lowering their threshold of activation.
Priming would favor subsequent responses at the site of restim-
ulation/target recognition, likely differing from the priming site
(Chaix et al., 2008; Lucas et al., 2007). Accordingly, interactions
between NK cells and accessory cells may occur in peripheral
tissues—where NK cell activation would result in IFN-g release,
able to activate macrophages—and/or in secondary lymphoid
organs—where NK cell-derived IFN-g would be pivotal for Th1
polarization (Boehm et al., 1997; Martı´n-Fontecha et al., 2004;1236 Cell Reports 4, 1235–1249, September 26, 2013 ª2013 The AuMoretta et al., 2006; Zanoni et al., 2005). The molecular signals
driving either activation or priming may only partially overlap,
requiring investigators to distinguish between these two
alternatives.
In this work, we aim at deciphering themechanisms underlying
NK cell activation during Gram-negative bacterial infections.
Activation was induced with E. coli and its major PAMP, the
lipopolysaccharide (LPS), for which an extensive body of knowl-
edge and a broad array of genetic tools to dissect its immune
response are available (Zanoni et al., 2011). TLR ligands
have been widely used in recent studies of NK cell activation
(Beuneu et al., 2009; Ebihara et al., 2010; Lucas et al., 2007;
McCartney et al., 2009; Miyake et al., 2009; Newman and Riley,
2007; Zanoni et al., 2005, 2012), endowing this choice with the
additional value of immediacy when linking this work to existing
literature.
Whereas the main emphasis was on the identification of
molecular events leading to IFN-g secretion—the chief antibac-
terial weapon of NK cells (Boehm et al., 1997; Granucci et al.,
2004)—we did not neglect to compare whether similar require-
ments applied to cytotoxic functions as well.
Here, we provide a comprehensive picture of the molecular
and cellular events underlying NK cell activation in vitro and
in vivo in response to LPS and Gram-negative bacteria. The
contribution of key cytokines in NK cell activation, such as inter-
leukin 15 (IL-15), may be revisited in light of our findings. Under-
standing the molecular mechanisms of NK cell activation has not
only important implications in fundamental biology but also a
marked translational impact, given the increasing interest in
exploiting and manipulating NK cell functions in immunotherapy
(Murphy et al., 2012).
RESULTS
DCs Are Essential Drivers of NK Cell Activation under
LPS-Induced Inflammatory Conditions
A productive DC-NK cell crosstalk may result in NK cell priming,
activation, or both. To assess whether NK cells were success-
fully primed by accessory cells, investigators have often restimu-
lated NK cells using target cells, antibodies against activating
receptors, or PMA/ionomycin before measuring IFN-g release
(Lucas et al., 2007; Martı´n-Fontecha et al., 2004). This strategy
captures the contribution of accessory cells in lowering the
threshold of NK cell activation, but it does not give insights into
direct NK cell activation right after (or even during) interaction
with DCs.
We investigated ex vivo NK cell activation in the absence
of restimulation. LPS was injected in the anterior footpad to
induce inflammation, and the percentage of IFN-g-producing
NK cells in the draining lymph node was measured at different
time points. IFN-g-positive NK cells could be identified with a
maximal peak of 15% at 5 hr after LPS injection (Figure 1A).
The same experiment was then repeated using CD11c.DOG
mice (Hochweller et al., 2008), in which CD11chigh cells (DCs)
express the diphtheria toxin (DT) receptor (DTR) and can be
depleted upon DT injection. In the absence of DCs, a profound
drop in the percentage of activated NK cells was observed (Fig-
ures 1B and S1).thors
These results argued in favor of a pivotal role of DCs in direct
NK cell activation (with immediate Th1-polarizing IFN-g release
[Martı´n-Fontecha et al., 2004]), in addition to the well-character-
ized NK cell priming (with IFN-g released in the periphery after
target encounter). Moreover, the requirement of DCs and the
kinetic of NK cell activation suggest that DC-NK cell interactions
take place in vivo early after inflammation onset.
DC-Derived IL-2, IL-18, and IFN-b Are Necessary and
Sufficient to Induce IFN-g Release by NK Cells in
Response to LPS In Vitro
Having confirmed that DCs activate NK cells, we next set to
characterize the underlying molecular framework, starting with
in vitro studies.
Upon stimulation with LPS, bone marrow (BM)-derived DCs
acquired the ability to directly elicit IFN-g production by NK cells.
TLR4 and both the adaptors MyD88 and Toll-IL-1 receptor (TIR)-
containing adaptor molecule 1 (TICAM1) (also known as TIR
domain-containing adaptor-inducing IFN-b, TRIF) were required
for this process (Figure 2A). Interestingly, NK cells could undergo
full activation in the absence of TLR4 and TICAM1 but notMyD88
(Figure 2B). Thus, despite that intracellular TLRsmight play a role
in promoting NK cell activation directly (Sivori et al., 2004), the
plasma membrane-bound TLR4 is dispensable.
The requirement for MyD88 but not TLR4 on NK cells (Fig-
ure 2B) for IFN-g release in LPS-stimulated DC-NK cell cocul-
tures suggested the involvement of IL-1 family receptors, which
signal through MyD88 (Dinarello, 2009). Among others, IL-1a,
IL-1b, and IL-18 are members of the IL-1 family. IL-1a and IL-
1b share the type I IL-1 receptor (IL-1R), whereas IL-18 is recog-
nized by IL-18R. We inhibited IL-1 activity with neutralizing
antibodies to IL-1R or with the recombinant IL-1R antagonist
(IL-1RA)—another member of the IL-1 family (Dinarello,
2009)—or with an anti-IL-1b-blocking antibody. The first two
treatments neutralize both IL-1a and IL-1b, whereas the latter
spares IL-1a. We found that in no case were NK cell-derived
IFN-g levels affected, ruling out a role for IL-1a and IL-1b in
DC-mediated NK cell activation (Figure 2C). By contrast, block-
ing IL-18 with either recombinant IL-18 binding protein (IL-
18BP) or neutralizing antibodies against the cytokine itself or
its receptor effectively dampened IFN-g release by NK cells
(Figure 2C). These results were confirmed by using NK cells pu-
rified from mice deficient for either IL-18R or IL-1R. Il18r1/
(but not Il1r1/) NK cells showed a marked reduction of IFN-
g release (Figure 2D). Similarly, IL-18-deficient BM-derived
DCs (BM-DCs) could not fully activate NK cells, and the addition
of recombinant IL-18 at the dose of 120 pg/ml completely
restored IFN-g production (Figure 2E). In summary, LPS-
matured DCs elicited efficient IFN-g release from NK cells
through the IL-18R-MyD88 axis.
The requirement of TICAM1 on DCs to obtain IFN-g release by
NK cells (Figure 2A) could imply a role for IFN-b, a cytokine totally
controlled by the LPS-activated TICAM1 pathway (Yamamoto
et al., 2002; Zanoni et al., 2011). To test this hypothesis, we
took advantage of IFN-b-deficient DCs. As shown in Figure 2F,
thesemutant cells were far less capable of stimulating IFN-g pro-
duction by NK cells than the wild-type (WT) counterpart. This
phenotype was reversed by the addition of recombinant IFN-bCell Re(rIFN-b) (Figure 2F), demonstrating that the impairment of NK
cell activation was truly due to the absence of IFN-b.
Concerning the requirement for MyD88 on DCs, we focused
our analysis on three cytokines known to be produced in a
MyD88-dependent way following LPS exposure and previously
described to contribute to IFN-g release by NK cells, namely
IL-12p70, tumor necrosis factor a (TNF-a), and IL-2. IL-12p70
has been classically linked to NK cell activation and IFN-g
release in humans in response to viral and bacterial stimuli (Fer-
lazzo et al., 2002; Fink et al., 2007; Muntasell et al., 2010; New-
man and Riley, 2007; Romo et al., 2011) and in mice during viral
infections (French and Yokoyama, 2003; Nguyen et al., 2000;
Orange and Biron, 1996). To investigate whether this was the
case in our system, we blocked IL-12 in DC-NK cell cocultures.
As shown in Figure 2G, IL-12 neutralization did not dampen
IFN-g production. Similarly, we ruled out a role for TNF-a (data
not shown). In contrast, we confirmed the contribution of IL-2
(Figure S2), as already shown by our group (Granucci et al.,
2004). Finally, we also excluded a role for CD70 stimulation (Fig-
ure S2), previously suggested to favor the release of IFN-g by NK
cells (Newman and Riley, 2007; Takeda et al., 2000).
In summary, we could establish that DC-derived IL-2, IL-18,
and IFN-b were essential signals for NK cell activation. To test
whether they were not only necessary but also sufficient to
trigger NK cell activation, we used recombinant IL-2, IL-18,
and IFN-b to stimulate NK cells. Each cytokine was added at
the concentration restoring full IFN-g production when NK cells
were cultured with the relevant cytokine-deficient DCs (Figures
2E and 2F; data not shown), thereby avoiding over- or understi-
mulation of NK cells. We found that the simultaneous stimulation
of NK cells by IL-2, IL-18, and IFN-b elicited IFN-g release,
whereas the lack of any of the three cytokines resulted in a totally
ineffective stimulation (Figure 2H).
In conclusion, LPS-activated DCs were able to directly acti-
vate NK cells in vitro by secreting three necessary and sufficient
signals: IL-2, IL-18, and IFN-b.
IL-18 and IFN-b Are Required for NK Cell Activation
In Vivo
Having established the in vitro relevance of IL-2, IL-18, and IFN-b
in NK cell activation under LPS-mediated inflammatory condi-
tions, we analyzed whether IL-18 and IFN-bwere required in vivo
for NK cell activation following exposure to whole Gram-negative
bacteria. In a previous work, we have already demonstrated the
essential role of IL-2 in NK cell activation during E. coli infections
(Granucci et al., 2004). In agreement with our in vitro data, 5 hr
after intravenous (i.v.) injection of E. coli, the fraction of IFN-g+
NK cells in the spleen was strongly diminished in IL-18- and
IFN-b-deficient mice (Figure 3A). By contrast, the absence of
IL-12p35 had a negligible effect on NK cell activation (Figure 3A),
again confirming our in vitro data (Figure 2G). This observation
was somehow in contrast with the established role of IL-12 in
NK cell activation during viral infections in mice (French and
Yokoyama, 2003; Nguyen et al., 2000; Orange and Biron, 1996)
and in response to viral and bacterial stimuli in humans (Ferlazzo
et al., 2003, 2004; Fink et al., 2007; Muntasell et al., 2010; Romo
et al., 2011). Because the upregulation of Il12b mRNA in DCs in
response to E. coli is relatively late, taking more than 4 hrports 4, 1235–1249, September 26, 2013 ª2013 The Authors 1237
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Figure 2. IL-18, IL-2, and IFN-b Are Necessary and Sufficient to Induce IFN-g Release in NK Cells Activated by LPS-Stimulated BM-DCs
After coculturing BM-DCs and NK cells for 18 hr, NK cell-derived IFN-g secreted in the supernatant was measured by ELISA.
(A) LPS-stimulated BM-DCs of the indicated genotype were cocultured with WT NK cells.
(B) LPS-stimulated WT BM-DCs were cocultured with NK cells of the indicated genotype. (A and B) Controls: DC + NK; DC + LPS; NK + LPS; DC; NK.
(C) NK cells and BM-DCs were cocultured in the presence of the indicated neutralizing Abs (or isotype controls) or recombinant proteins.
(D) NK cells of the indicated genotype were cocultured with LPS-stimulated WT BM-DCs.
(E and F) LPS-stimulated BM-DCs of the indicated genotype were cocultured withWTNK cells. Where indicated, increasing doses of rIL-18 or rIFN-bwere added
to the cocultures.
(G) WT BM-DCs and WT NK cells were cocultured in the presence of LPS and the indicated neutralizing Ab (or isotype control). (D–G) Results are shown as
percentage of IFN-g release relative to WT NK cells activated by LPS-stimulated WT BM-DCs.
(H) NK cells were cultured without BM-DCs in the presence or absence of rIL-2 (1 ng/ml), rIL-18 (120 pg/ml), and rIFN-b (200 U/ml).
(A and B) nR 4. (C–H) nR 3. Statistical significance was determined with ANOVA followed by Dunnett’s multiple comparison test (A and B, white-and-black
stripes in [C] and [D]), a two-tailed one-sample t test (solid black in [C], [E], and [F]) or a two-tailed two-sample t test (all others in [C] and [G]). Error bars depict SEM.
*, p < 0.05; **, p < 0.01; ***,p < 0.001; ****, p < 0.0001; ns, not significant.
See also Figure S2.
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Figure 3. Role of IL-18, IFN-b, and IL-12 in Antibacterial Immunity
(A–C)Micewere challenged i.v. withE. coli. NK cell activation at 5 (A) and 18 (B) hr was determined in the indicated knockoutmice. Residual bacterial burden in the
spleen was measured at 18 hr (C). (A and B) n = 4–8 mice per group from two independent experiments. (C) n = 6–27 mice per group from four independent
experiments. Statistical significance was determined with ANOVA followed by Dunnett’s multiple comparison test. Error bars depict SEM. *, p < 0.05; **, p < 0.01;
***, p < 0.001; ****, p < 0.0001; ns, not significant. See also Figure S3.(Granucci et al., 2001), we hypothesized that IL-12, although
dispensable at early time points, could rather play a role in main-
taining NK cell activation at late time points. Therefore, we
measured the effect of IL-12p35 deficiency on IFN-g secretion
by NK cells 18 hr after bacterial injection. As shown in Figure 3B,
a significant decrease in the fraction of IFN-g+ NK cells could be
observed in IL-12p35-deficient animals. The contribution of IL-18
and IFN-b was detectable also at late time points (Figure 3B).
Consistent with the roles of IL-18, IFN-b, and IL-12 in NK cell acti-
vation,E. coli clearance in the spleenwas significantly reduced in
IL-18-, IFN-b-, and IL-12p35-deficient mice 18 hr after bacterial
challenge (Figure 3C). These data indicate that, in addition to
IL-2 (Granucci et al., 2004), IL-18 and IFN-b are required in vivo
to initiate the process of NK cell activation during Gram-negative
bacterial infections and that IL-12 is later required tomaintain the
size of the activated NK cell population.
DC-Derived IL-2, IL-18, and IFN-b Are Required for Full
IFN-g Release by NK Cells In Vivo
Wenext aimed to establish whether DCs had a critical role in vivo
in secreting the cytokines IL-2, IL-18, and IFN-b, which initiate
the process of NK cell activation. Because the in vivo responses
to E. coli and LPS at early time points were almost completely
superimposable (Figures S3 and 3A)—confirming previous
observations that DC- and macrophage-driven responses to
E. coli were mediated by TLR4 (Poltorak et al., 1998; Takeuchi
et al., 1999; Zanoni et al., 2011)—we performed the following
experiments using LPS as a stimulus.
We conceived a mixed BM chimera model to largely restrict a
candidate cytokine deficiency to DCs (Figure 4A). To this aim, we
took again advantage of CD11c.DOG mice (Hochweller et al.,
2008). For labeling, these animals were crossed with ubiqui-
tin.GFP transgenic mice, giving rise to DOG-GFP double trans-
genic (dTg) animals. In our mixed BM chimeras, 80% of donor
cells came from DOG-GFPdTg mice and 20% came from mice
deficient for a selected cytokine—IL-2, IL-18, or IFN-b—orCell ReTLR4, as a negative control (Figure 4A). Upon injection of DT,
only DOG-GFPdTg-derived CD11chigh cells were ablated. There-
fore, precursors from the DT-insensitive but cytokine-deficient
fraction were allowed to replenish the DC compartment over
time. When DT was injected for long enough to allow full replen-
ishment of the DC niche (1 week in our studies), the largemajority
of DCs were GFP-negative and, consequently, deficient for the
cytokine under investigation (Figure S4A). By contrast, the NK
cell compartment segregated according to the initial ratio of
reconstitution, namely 80% DOG-GFPdTg and 20% knockout
(KO) for a given cytokine, even after DT treatment (Figure S4B).
Therefore, most radiation-sensitive non-DC cells, including NK
cells, did not bear any genetic deficiency, regardless if DT was
injected or not, and the minor cytokine-KO fraction was readily
distinguishable by GFP expression (Figure 4A). Importantly, the
DT treatment did not alter the percentage of activated NK cells
after LPS administration (Figure S4C). Moreover, cytokine-defi-
cient NK cells could be activated as efficiently as WT NK cells
(Figure S4D), indicating that the genetic mutations under investi-
gation did not intrinsically affect NK cell functionality.
LPS was injected in mixed BM chimeras after 1 week of daily
DT treatment, and NK cell activation in the spleen was assessed
5 hr later (Figure 4A). In line with our expectations, the IFN-g+
fraction of NK cells was reduced when DCs lacked any of the
three cytokines (Figure 4B), confirming the requirement for DC-
derived IL-2, IL-18, and IFN-b in NK cell activation in vivo upon
LPS stimulation.
IL-15 Is Required for NK Cell Activation in Response to
IFN-b and Can Be Produced by Both DCs and NK Cells
Recently, several investigators have reported a role of the trans-
presented IL-15 in DC-mediated NK cell activation (Koka et al.,
2004; Lucas et al., 2007; Mortier et al., 2008; Newman and Riley,
2007). In this context, type I IFNs would exert their function
by eliciting the production of IL-15 from DCs (Lucas et al.,
2007; Zhang et al., 1998). To investigate whether this was theports 4, 1235–1249, September 26, 2013 ª2013 The Authors 1239
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Figure 4. DC-Derived IL-2, IL-18, and IFN-b Are Required for Full NK Cell Activation In Vivo
(A) Experimental design. DOG-GFPdTgmicewere lethally irradiated and reconstitutedwith BMdonor cells coming for 80% fromDOG-GFP dTgmice and for 20%
from mice KO for the indicated genes. After full recovery, mice were treated with DT for 1 week to deplete cytokine-sufficient DCs, allowing KO precursors to
replenish the DC niche. As a result, the cytokine deficiency was largely restricted to DCs. One day after the last DT injection, mice were challenged with LPS, and
the percentage of activated (IFN-g+) NK cells was determined at 5 hr.
(B) Results of the experiment depicted in (A). NK cells were gated as GFP+ CD49b+ CD3. n = 6–12 mice per group from three independent experiments.
Statistical significance was determined with ANOVA followed by Dunnett’s multiple comparison test. ****, p < 0.0001.
See also Figure S4.case in our experimental conditions, we tested if the addition of
rIL-15 restored IFN-g secretion by NK cells cocultured with LPS-
activated, IFN-b-deficient DCs. Figure 5A shows that this was
indeed the case. This observation confirmed the published
finding (Lucas et al., 2007) that IFN-b exerts its stimulatory func-
tion by inducing IL-15 production.
Surprisingly, however, the ability of IL-15-deficient DCs to
activate NK cells was largely preserved (Figure 5B). This could
be explained if DCs were not the only source of IL-15. In that
case, NK cells should be able to self-produce IL-15 upon IFN-
b stimulation. To test this hypothesis, we first measured the abil-
ity of NK cells to produce IL-15 in response to IFN-b. For this
experiment, NK cells were identified as CD49+ CD3 CD122+
cells. As shown in Figure 5C, NK cells could indeed produce
and expose at the cell surface IL-15 upon stimulation with IFN-
b. In agreement with this observation, we also observed the up-
regulation of Il15 mRNA in NK cells exposed to IFN-b in both
mouse and man (Figures S5 and S6). Moreover, to corroborate
the mechanism of IL-15 production, we analyzed IL-15Ra-defi-
cient NK cells. The prediction of this experiment was that IL-15
would not be detectable at the cell surface, due to its instability
when not bound to the a receptor (Mortier et al., 2008). Indeed,
IL-15 was not detectable in Il15ra/ NK cells, either at the cell
surface or in the cytoplasm (Figure 5C). Conversely, in WT NK
cells, IL-15 could be detected intracellularly after IFN-b stimula-
tion and brefeldin A treatment (Figure 5C).
Having established that NK cells were a source of IL-15 as
much as DCs, we cocultured DCs and NK cells (CD49b+ CD3;
purity >99%), both isolated from IL-15-deficient animals. Now,
under conditions where both DC- and NK cell-derived IL-15
was missing, IFN-g production by NK cells was totally impaired
(Figure 5D). Consistently, when anti-IL-15- or anti-IL-15Ra-
blocking antibodies were added to cultures of NK cells stimu-
lated with IL-2, IL-18, and IFN-b, a strong reduction in their ability
to secrete IFN-g was observed (Figure 5E). Our results indicate
not only that IL-15 is indeed required for NK cell activation, as1240 Cell Reports 4, 1235–1249, September 26, 2013 ª2013 The Aupreviously shown (Lucas et al., 2007), but also that both DCs
and NK cells can be the source of this cytokine, at least in vitro.
Next, we tested whether this finding held true in vivo. To this
purpose, we generated mixed chimeric mice, in which DCs,
NK cells, or both were IL-15-deficient, by adapting themodel de-
picted in Figure 4A. In this variation (Figure 6A), we took advan-
tage of NKp46.DTR mice, in which NK cells are labeled (GFP+)
and can be conditionally depleted (DTR+) upon DT treatment
(Walzer et al., 2007). To target both DCs and NK cells,
NKp46.DTR mice were crossed with CD11c.DOG mice. Recip-
ient mice (any one of DOG-GFPdTg, NKp46.DTR, or DOG-
GFPdTg 3 NKp46.DTR mice) were irradiated and reconstituted
with mixed BM cells derived for 20% from IL-15-deficient mice
and for 80% from donors of the same genotype as recipient
mice. Upon DT injection, DCs, NK cells, or both NK cells and
DCs were ablated and their niche was replenished by IL-15-defi-
cient precursors, yielding Il15/ DCs, Il15/ NK cells, or both
Il15/ DCs and Il15/ NK cells, respectively (Figures 6A and
S7). Chimericmicewere then injectedwith LPS, and the percent-
age of IFN-g-positive NK cells in the spleen was determined. NK
cell activation was totally impaired only when both DCs and NK
cells were unable to produce IL-15 (Figures 6B and S7). These
results confirmed our in vitro observation that IL-15 was required
for NK cell activation induced by LPS and that both DCs and NK
cells could be sources of IL-15, in response to type I IFNs.
In agreement with our observations, we also found a clear
increase in Il15ra mRNA expression by both murine and human
NK cells after IFN-b exposure (Figures 6C and S6). This is in line
with the observation by French et al. (2006) of IL-15Ra upregu-
lation by NK cells during murine cytomegalovirus (MCMV)
infections. Moreover, functional outcomes observed using IL-
15-deficient DCs and NK cells could be recapitulated by their
Il15ra/ counterparts (Figures 6D–6F), as it may be expected
from the observation that IL-15 and IL-15Ra are physiologically
found in complex (Mortier et al., 2008). Indeed, when IL-15Ra-
deficient NK cells were stimulated with IL-2, IL-18, and IFN-b,thors
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Figure 5. IL-15 Is Required for NK Cell Activation and Can Be Produced by Both DCs and NK Cells In Vitro
(A and B) IFN-g production by WT NK cells stimulated with LPS-activated BM-DCs of the indicated genotype. Where indicated, rIL-15 was added at 100 ng/ml.
Controls: DC + NK; DC + LPS; NK + LPS; DC; NK; in (A), ± rIL-15.
(C) Immunocytofluorescence ofWT andmutant NK cells treated or not with 200 U/ml rIFN-b for 3 hr.Where indicated, BFAwas added. IL-15 (green) was detected
with an indirect antibody staining, whereas the membrane (red) was counterstained with cholera toxin B.
(D) IFN-g production by WT or IL-15-deficient NK cells cocultured with LPS-activated WT or IL-15-deficient BM-DCs. Controls: DC + NK; DC + LPS; NK + LPS;
DC; NK.
(E) IFN-g production by WT NK cells stimulated with rIL-2 (1 ng/ml), rIL-18 (120 pg/ml), and rIFN-b (200 U/ml) in the presence of the indicated neutralizing an-
tibodies (or isotype control).
(A, D, and E) nR 3. Statistical significance was determined with ANOVA followed by Dunnett’s multiple comparison test. (B) nR 3. Statistical significance was
determined with a two-tailed t test. (C) n = 2. Error bars depict SEM. **, p < 0.01; ****, p < 0.0001; ns, not significant.
See also Figures S5 and S6.IFN-g release was severely impaired (Figure 6D). This was not
due to intrinsic unresponsiveness of Il15ra/ NK cells, because
a type I IFN-independent stimulation with a well-described com-
bination of activating cytokines produced during viral infections,
IL-12 and IL-18 (Andrews et al., 2003; Fehniger et al., 1999;
Robinson et al., 1997), resulted in an adequate release of
IFN-g by Il15ra/ NK cells, far larger than when cells received
a type I IFN-dependent stimulation (Figure 6D). This is in agree-
ment with published reports of functional integrity of Il15/ and
Il15ra/ NK cells (Sun et al., 2009). Consistent with the defec-
tive response of Il15ra/ NK cells to IL-2, IL-18, and IFN-b,
clear activation impairment was also observed in DC-NK cell
cocultures when both cell types were IL-15Ra-deficient
(Figure 6E).
The observation that IL-15 could be self-produced by NK cells
opened the question whether NK cell-derived IL-15 could only
be effective autocrinally, via IL-15Ra-mediated cis presentation,Cell Reor also paracrinally, through trans presentation between different
NK cells. To investigate this question, WT and Il15ra/ NK cells
were cocultured at different ratios and activated with IL-2, IL-18,
and IFN-b. We reasoned that IL-15Ra-deficient NK cells would
produce IFN-g only if IL-15 could be trans-presented by juxta-
posed IL-15Ra-competent NK cells. Moreover, the efficiency
of trans presentation (but not cis presentation) would be miti-
gated at low densities of IL-15Ra-sufficient cells. We found
that, independently of the ratio between WT and Il15ra/ NK
cells, only WT NK cells could produce IFN-g (Figure 6F), indi-
cating that NK cell-derived IL-15 can only operate in an autocrine
way via cis presentation.
NK Cell Cytotoxic Activity Requires IFN-b and IL-15 but
Not IL-2 or IL-18
In addition to IFN-g production, NK cells are endowed with
another major function, namely cytotoxic activity againstports 4, 1235–1249, September 26, 2013 ª2013 The Authors 1241
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Figure 6. IL-15 Triggered by IFN-bCan Be Presented by IL-15Ra in cis by NK Cells and in trans by DCs and Is Required for NK Cell Activation
In Vivo
(A) Experimental design for (B). Chimeric mice were generated and treated with DT as shown to obtain the following phenotypes: IL-15-deficient DCs and IL-15-
sufficient (GFP+) NK cells using DOG-GFPdTg recipients (top panel); IL-15-sufficient DCs and IL-15-deficient (GFP) NK cells using NKp46.DTR recipients
(middle panel); IL-15-deficient DCs and IL-15-deficient (GFP) NK cells using DOG-GFPdTg 3 NKp46.DTR recipients (bottom panel). All recipient mice were
reconstituted with BM cells for 80% from donors of the same genotype as the recipient and for 20% from Il15/ (or WT as a control) animals. Chimeric mice were
treated with DT for 1 week to deplete IL-15-sufficient DCs, NK cells, or both, allowing IL-15-deficient progenitors to proliferate and replenish their niches. One day
after the last DT injection, mice were challenged with LPS, and the percentage of activated (IFN-g+) NK cells was determined at 5 hr.
(B) Results of the experiment depicted in (A).
(C) Il15ra mRNA expression in sorted WT NK cells (CD49b+CD3) at the indicated time points upon rIFN-b exposure (200 U/ml). Data are expressed as relative
expression over the basal level measured in unstimulated cells at the same time point.
(D) Sorted NK cells (CD49b+CD3) of the indicated genotype were activated with either rIL-2 (1 ng/ml) + rIL-18 (120 pg/ml) + rIFN-b (200 U/ml) or rIL-12
(100 pg/ml) + rIL-18 (120 pg/ml). After 18 hr, IFN-gwas measured in cell-free supernatants. Absolute values (top) or relative ratios (Il15ra/ over WT, bottom) are
shown. Removing any recombinant cytokine from either cocktail results in an ineffective stimulation (controls).
(E) BM-DCs and NK cells fromWT or Il15ra/ (KO) mice were cocultured in the presence of LPS for 18 hr before measuring IFN-g. Controls: DC + NK; DC + LPS;
NK + LPS; DC; NK.
(legend continued on next page)
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Figure 7. NK Cell Cytotoxic Activity Re-
quires IFN-b and cis- or trans-Presented
IL-15
(A) BM-DCs of the indicated genotype, either un-
treated or stimulated by LPS, were cocultured with
graded numbers ofWTNK cells for 6 hr. Afterward,
YAC-1 target cells were added for 3 additional hr
to measure NK cell-mediated lysis. One repre-
sentative experiment out of six is shown.
(B–D) MHC class I-sufficient and deficient sple-
nocytes labeled with different concentrations of
CFSE were injected i.v. at 1:1 ratio together with
LPS to activate NK cells. One day later, spleen
cells were analyzed by flow cytometry and the ratio
between sensitive (MHC-I-deficient) and resistant
(MHC-I-sufficient) target cells was determined. (B)
In vivo cytotoxic activity of NK cells in CD11c.DOG
mice treated or not with DT to deplete DCs. (C)
In vivo cytotoxic activity of NK cells in the indicated
knockout mice. (D) In vivo cytotoxic activity of
NK cells in mixed BM chimera mice (strategy
illustrated in Figure 6A) bearing Il15/ DCs and
Il15+/+NK cells, Il15+/+DCs and Il15/NK cells, or
Il15/ DCs and Il15/ NK cells.
(B–D) n = 6mice per group from three independent
experiments. Statistical significance was deter-
mined with a one-tailed t test (B) or with ANOVA
followed by one-tail Dunnett’s multiple compari-
son test (C and D). Error bars depict SEM. *, p <
0.05; **, p < 0.01; ***, p < 0.001; ns, not significant.missing- or altered-self targets (Lanier, 2005). Therefore, we
asked whether IL-2, IL-18, and IFN-b had a role in promoting
NK cell cytotoxicity as well. The NK cell lytic capacity was first
investigated in vitro. As shown in Figure 7A, NK cell cytotoxicity
was poor in the absence of DCs. The addition of DCs greatly
boosted NK cell-mediated killing. IL-2 and IL-18 displayed no
role in the DC-mediated enhancement of NK cell cytotoxic activ-
ity. By contrast, IFN-b was essential.
We then analyzed the requirements to activate the NK cell
cytotoxic activity in vivo by measuring the selective killing of
b-2 microglobulin-deficient target cells. First, we aimed at con-
firming the finding that DCs were required to induce the NK
cell cytotoxic function upon LPS administration (as observed
for IFN-g production). As shown in Figure 7B, the capacity of
NK cells to efficiently kill target cells was in fact dependent on
the presence of DCs. Second, we analyzed the cytotoxic activity
of NK cells in IL-2-, IL-18-, or IFN-b-deficient mice. We observed
that the cytotoxic activity of NK cells was completely preserved
following LPS injection in IL-18-deficient and IL-2-deficient mice
but not in IFN-b-deficient mice (Figure 7C). Because the role of
IFN-b was confirmed both in vitro and in vivo, we asked whether
that was mediated by IL-15. To this end, we performed a cyto-(F) NK cells sorted (CD49b+ CD3) from IL-15-sufficient Ubiquitin. GFP (WT) or Il1
rIL-18 (120 pg/ml) + rIFN-b (200 U/ml). After 5 hr (2 hr with cytokines and 3 hr with b
staining.
(B) n = 4–6 mice per group from three independent experiments. (C and D) nR 3. (
Sidak’s ([B], [D] top, [F]) or Dunnett’s (E) multiple comparison tests. A two-tail t test
****, p < 0.0001; ns, not significant.
See also Figures S5, S6, and S7.
Cell Retoxicity experiment in mixed BM chimeric mice, in which DCs,
NK cells, or both DCs and NK cells had been deprived of the
capacity to produce IL-15 (similar to the experimental setting de-
picted in Figure 6A). Interestingly, the lytic activity of NK cells was
totally inhibited only when both DCs and NK cells were unable to
produce IL-15 (Figure 7D). This is in line with our findings on the
role of IL-15 for NK cell-derived IFN-g release (Figure 6B), once
again indicating that IL-15 was required to activate NK cell cyto-
toxic functions, regardless of the source (DCs or NK cells).
In conclusion, the cytotoxic activity of NK cells in LPS-induced
inflammatory conditions depends on conventional DCs, IFN-b
and IL-15. IL-15 can be either trans-presented by DCs or cis-
presented by NK cells.
DISCUSSION
NK cell activation had long been regarded as a cell autonomous
event. The balance of signals arising from activating and inhibi-
tory receptors, engaged by transformed or infected cells, would
ultimately determine the magnitude of NK cell responses (Horo-
witz et al., 2012). This oversimplified view was first called into
question by the finding that DCs can potently stimulate the5ra/ mice were mixed at different ratios and stimulated with rIL-2 (1 ng/ml) +
refeldin A), the fraction of IFN-g-secreting cells was determined by intracellular
E and F) n = 4. Statistical significance was determined with ANOVA followed by
was used to analyze (D) bottom. Error bars depict SEM. *, p < 0.05; **, p < 0.01;
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antitumor functions of NK cells (Fernandez et al., 1999). Details of
such interaction began to emerge, and the figure being revealed
dramatically altered our understanding of NK cell biology (New-
man and Riley, 2007). Now, parallels between NK cells and
T cells are being drawn, as illustrated by the proposed concept
of DC-mediated NK cell priming (Chaix et al., 2008; Koka et al.,
2004; Lucas et al., 2007), echoing naive T-cell priming. Essen-
tially, a shift of focus from the innate features to the lymphocytic
nature of NK cells has occurred. However, differently from
T cells, details of DC-NK cell interactions are scattered and
hard to reconcile (Newman and Riley, 2007). Several molecular
signals have been implicated in priming and/or activation, two
nonoverlapping events, yet often blearily distinguished in the
literature. Nonetheless, to date, a set of signals not only neces-
sary but also sufficient for NK cell activation has not been iden-
tified, especially in response to Gram-negative bacteria.
We proved that DCs are the accessory cells required not sim-
ply for NK cell priming, as previously proposed (Lucas et al.,
2007), but in fact for direct NK cell activation. Indeed, IFN-g
was immediately released, even in the absence of restimulation
(Figure 1A), and that was dependent on the presence of DCs
(Figure 1B). We ruled out the possibility that NK cells are able
to sense LPS directly (Figure 2B). Indeed, several studies re-
ported a role for autonomous recognition of TLR agonists by
NK cells (Becker et al., 2003; Chalifour et al., 2004; Hart et al.,
2005; Lauzon et al., 2006; Sivori et al., 2004, 2006, 2007; Tsuji-
moto et al., 2005). This is not the case for TLR4, as TLR4-defi-
cient NK cells displayed no defect in IFN-g release (Figure 2B).
By contrast, TLR4 was required on DCs in vitro and in vivo, high-
lighting the accessory cell-dependent nature of NK cell activa-
tion in this context (Figures 2A and 4B).
Then, we showed that full IFN-g release by NK cells is elicited
by three DC-derived cytokines secreted in response to LPS:
IL-2, IL-18, and IFN-b (Figures 2 and 4). A crucial role of IFN-b
is to trigger IL-15 release by both DCs and NK cells. In turn,
IL-15 can act in a dual fashion: paracrinally (trans-presented by
DCs to NK cells), as previously shown (Lucas et al., 2007), but
strikingly also in an autocrine way, via cis presentation by an
NK cell to itself (Figures 5, 6, and 7D). IL-15 is preassembled in
complex with IL-15Ra in the endoplasmic reticulum/Golgi
compartment (Mortier et al., 2008). Then, IL-15Ra ‘‘presents’’
IL-15 to IL-2/15Rb/g, initiating intracellular signaling (Koka
et al., 2004). Such a uniquemechanism can operate both in trans
(IL-15Ra and IL-2/15Rb/g are expressed on two different cells,
usually of different type; Brilot et al., 2007; Koka et al., 2004)
and in cis (IL-15Ra and IL-2/15Rb/g are expressed on the
same cell; Olsen et al., 2007; Rowley et al., 2009). The role of
IL-15 trans presentation from DCs to NK cells is seen as largely
prevalent during NK cell activation (Koka et al., 2004; Lucas
et al., 2007; Mortier et al., 2008). However, in line with our obser-
vation that IFN-b-stimulated NK cells express both IL-15 and
IL-15Ra (Figures 5C, 6C, S5, and S6), we found that cis and trans
presentation are codominant mechanisms in NK cell activation.
Differently from the prevalent view, we show that, in the absence
of IL-15 trans presentation, NK cells can still undergo activation,
thanks to their IL-15 cis-presenting activity. Indeed, only when
both DCs and NK cells were IL-15 (or IL-15Ra) deficient was
NK cell activation severely impaired (Figures 5D, 6B, and 6E).1244 Cell Reports 4, 1235–1249, September 26, 2013 ª2013 The AuConversely, when IL-2, IL-18, and IFN-b were used to stimulate
NK cells (Figures 5E, 6D, and 6F), IL-15 presentation could solely
take place in cis. It is worth noting that there have been other
reports of IL-15Ra upregulation in NK cells, such as in response
toMCMV (French et al., 2006). However, because IL-15 neither is
secreted by DCs as free protein nor dissociates from IL-15-IL-
15Ra complexes (Mortier et al., 2008), there is no free soluble
IL-15 available to bind to unloaded IL-15Ra under physiological
conditions. Consequently, the functional significance of IL-15Ra
expression by NK cells remained elusive. We found that IL-15
can be expressed by NK cells in an IL-15Ra-dependent fashion
(Figures 5, 6, and S6), thereby providing a rationale for the
observed IL-15Ra expression in NK cells. Altogether, our find-
ings call for a revaluation of the contribution of IL-15 cis presen-
tation in DC-mediated NK cell activation and possibly in other
biological processes relying on IL-15. Whereas our discovery
of physiological IL-15 cis presentation focused on NK cell
biology, it may likely impact on several other IL-15-dependent
processes as long as type I IFNs are involved.
The short-tailed IL-2Ra and IL-15Ra are not thought to be
endowed with any signaling properties, although this notion
has been questioned, at least for IL-15Ra (Pohl et al., 2011; Cas-
tro et al., 2011). However, the simultaneous requirement for IL-2
and IL-15, both engaging the IL-2/15Rb/g-STAT5 axis, to
achieve an efficient DC-mediated NK cell activation (Figures
2H, 4B, 5, 6, and S2) points to nonredundant signaling properties
of the two cytokines. This is also supported by the finding that
IL-15 but not IL-2 contributes to NK cell cytotoxicity in response
to LPS (Figure 7). The conundrum is even more intriguing in view
of a recent study that could not detect any substantial signaling
divergence between IL-2 and IL-15 (Ring et al., 2012), leaving
observers to speculate that only receptor occupancy and/or
signaling context may solve the paradox (Ikemizu et al., 2012).
However, the case of DC-mediated NK cell activation, where
the signaling contexts of IL-2 and IL-15 are similar, increases
the challenge and provides fertile ground for future investigation.
Why IL-15 is controlled downstream of type I IFNs (Zhang
et al., 1998) rather than being directly elicited by PAMP recogni-
tion asmost myeloid cell-derived cytokines is an intriguing ques-
tion. By uncovering that lymphoid cells, such as NK cells, can
also produce IL-15, this missing direct link between pattern
recognition and IL-15 release appearsmore reasonable. Another
point is that IL-15 contributes not only to activation but also to
survival of NK cells and memory CD8+ T cells (Berard et al.,
2003; Brilot et al., 2007; Burkett et al., 2004; Huntington et al.,
2009; Ranson et al., 2003), that is, cytotoxic lymphocytes
involved in immediate first-line responses. Large amounts of
type I IFNs are produced during infections by both immune
and nonimmune cells (Sen, 2001). It is tempting to link these
two observations by speculating that, during infections, any
type I IFN-secreting cell (not only DCs) might promote NK cell
survival by eliciting IL-15, with the final outcome of strengthening
the immune response. Notably, this would be different from
steady-state homeostasis of NK cells, which is a noncell auton-
omous event (in that IL-15-competent NK cells die in an IL-15-
deficient recipient) and does not depend on the presence of
type I IFNs (Huntington et al., 2009; Ma et al., 2006). The mech-
anism of IL-15-dependent survival would also be different fromthors
IL-15-dependent activation, as we showed how the latter ismore
strictly dependent on DCs (Figures 5, 6, and 7). Nevertheless, IL-
15-dependent survival and activation would conceivably share
portions of their underlying molecular mechanisms. In this light,
the dependence of IL-15 production from type I IFNs, which
would be reasonable for the dynamic of NK cell survival during
infections, might be conserved during the process of NK cell
activation, where direct IL-15 production by DCs in response
to PAMPs would otherwise be expected, as it occurs for most
cytokines. We speculate that another reason for the type I IFN-
dependence of IL-15 might be its previously unappreciated cis
presentation, which we uncovered here (Figures 5, 6, and 7).
Indeed, because NK cells cannot sense LPS directly (Figure 2B),
they would not be able to produce IL-15, was it placed directly
downstream of PRRs. Conversely, the regulation through a sol-
uble mediator (such as IFN-b) allows even cells not equipped
to directly recognize PAMPs (such as NK cells) to produce cyto-
kines (such as IL-15) essential for immune responses.
IL-1b and IL-18 are usually released in a two-step process—
priming and inflammasome activation (Schroder and Tschopp,
2010)—and LPS is thought to provide only priming. However,
there are instances when LPS alone is able to trigger the secre-
tion of biologically active IL-1 and IL-18. This is the case, for
instance, of human monocytes (Netea et al., 2009). We have
also shown that ultrapure rough LPS (the type used in this study)
alone is able to trigger ASC-dependent inflammasome activation
and subsequent IL-1b and IL-18 production in DCs (Zanoni et al.,
2012).
Finally, we also investigated the molecular requirements of
productive DC-NK cell interactions in terms of enhancement
of cytotoxic responses. DC-derived IL-2 at physiological con-
centrations was previously shown to be dispensable for eliciting
cytotoxic responses in vitro (Granucci et al., 2004). In the pre-
sent study, we confirmed this observation in vivo, and we
also report that IL-18 is similarly dispensable (Figure 7).
Conversely, in agreement with the literature (Nguyen et al.,
2002), we found that DC-derived IFN-b strongly boosts the
cytotoxic responses of NK cells. The effect of IFN-b may be
partially direct, but surely, its indirect effect through the induc-
tion of IL-15 is critical (Figure 7D). Again, as already seen for
IFN-g secretion (Figures 5D, 6B, and 6E), the lack of IL-15 on
DCs can be functionally complemented by IL-15 cis presented
by NK cells (Figure 7D).
Our results shed light on the mechanisms underlying NK cell
activation in vivo in response to E. coli and its major bacterial
PAMP, LPS. A precise understanding of the biological program
governing NK cell responses might provide a framework for
next-generation immunotherapeutic strategies based on the
manipulation of NK cell functions.
EXPERIMENTAL PROCEDURES
Mice
All mice, housed under specific pathogen-free conditions, had been on a B6
background for at least 12 generations and were used at 7–12 weeks of
age. Il12a/ mice were B6 albino. The genetic background of B6 albino
mice is identical to that of B6 mice, as confirmed by The Jackson Laboratory.
Experiments were performed using protocols approved by the Institutional
Animal Care and Use Committee of the University of Milano-Bicocca.Cell ReWT animals were supplied by Harlan Italy. Il1r1tm1Inx (Il1r1/), Il2tm1Hor
(Il2/), Il18r1tm1Aki (Il18r1/), Il18tm1Aki (Il18/), and Ticam1Lps2 (Ticam1/)
mice were purchased from The Jackson Laboratory. Il12atm1Jm (Il12a/)
and Il15ratm1Ama (Il15ra/) mice were kindly provided by L. Romani (University
of Perugia, Italy) and S. Bulfone-Paus (University of Manchester, UK). Il15tm1Imx
(Il15/) animals were from Taconic. Myd88tm1Aki (Myd88/) and Tlr4tm1Aki
(Tlr4/) mice were provided by S. Akira (IFReC, Japan). Ifnb1tm1Tl (Ifnb1/)
mice were supplied by S. Weiss (Helmholtz Centre for Infection, Germany).
Ubiquitin.GFP (Ikawa et al., 1998) and B2mtm1Unc (B2m/) mice were ob-
tained from M. Battaglia (San Raffaele Telethon Institute for Gene Therapy,
Italy); NKp46.DTR (Walzer et al., 2007) mice, in which NK cells are labeled
with GFP and express the DTR for conditional DT-mediated depletion, were
a kind gift from E. Vivier (Centre d’Immunologie de Marseille-Luminy, France).
CD11c.DOG mice have already been described (Hochweller et al., 2008).
Briefly, this transgenic model expresses the DTR under the control of a cloned
CD11c promoter, allowing selective depletion of DCs (CD11chigh) upon DT
treatment. The CD11c promoter region cloned in CD11c.DOG mice is longer
than in former CD11c.DTR/GFP mice (Jung et al., 2002), resulting in a highly
faithful DTR expression, which in turn allows DT-mediated ablation of DCs
for an extended time without toxicity.
To deplete DCs in experiments where LPS was delivered subcutaneously
(s.c.) (Figure 1B), DT was injected s.c. 4 hr before LPS challenge, as DC deple-
tion was already highly effective and specific at this time point (Figure S1).
Conversely, when LPS was delivered i.v., CD11c.DOG mice received a single
intraperitoneal (i.p.) injection of 16 ng DT (Sigma-Aldrich) per gram of body
weight (gbw) at day 1.
In order to largely restrict a cytokine deficiency to DCs, mixed BM chimeras
were generated (Figure 4A) as follows. CD11c.DOG/ubiquitin.GFP double-
transgenic (DOG-GFPdTg) mice were exposed to lethal (950 rad) whole-
body irradiation and reconstituted with 5 3 106 BM cells and then allowed to
recover for at least 2 months with antibiotics before being used for experi-
ments. Control nonreconstituted mice did not survive, confirming the lethality
of irradiation. Twenty percent of donor BM cells came from mice deficient
for the cytokine under examination, whereas the remaining 80% came from
DOG-GFPdTg mice. A similar strategy was used to generate mixed BM
chimeras based on NKp46.DTR donor cells, as described in the main text
and depicted in Figure 6A. Mixed BM chimeras received a daily i.p. injection
of 16 ng DT/gbw for 7 days. This allowed enough time for niche replenishment
by differentiating precursors, restricting the repopulation potential to the
DT-insensitive (and deficient for a selected cytokine) fraction only.
Cells
All cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM)-10
complete medium: IMDM, 10% heat-inactivated fetal bovine serum (FBS)
(EuroClone), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 50 mM 2-mercaptoethanol (Sigma-Aldrich).
BM-DCs were generated by culturing BM precursors, flushed from femurs,
in granulocyte-macrophage colony-stimulating factor-supplemented medium
for 8–10 days, as described (Granucci et al., 2001; Inaba et al., 1992).
NK cells were purified from red blood cell (RBC)-lysed splenocytes by
magnetic-activated cell sorting (MACS) positive selection using CD49b (DX5)
microbeads (Miltenyi Biotec). Purity was assessed by fluorescence-activated
cell sorting (FACS) and was routinely between 93% and 96%. Alternatively,
NK cells were first enriched by MACS negative selection for Ly-6G (1A8),
CD19 (6D5), and CD3ε (145-2C11) using biotinylated antibodies (Abs) and
streptavidin microbeads and then stained with anti-CD49b and sorted with a
FACSAria II (BD Biosciences). Purity was consistently greater than 99.5%.
MACS-selected and FACS-sorted NK cells produced similar results in our
experiments. Where indicated, NK cells were identified and sorted as
CD49b+CD3CD122+ cells.
YAC-1 cells were purchased from the American Type Culture Collection.
Human peripheral blood mononuclear cells (PBMCs) were isolated from
EDTA-anticoagulated blood using standard Ficoll density gradient centrifuga-
tion. PBMCs were cryopreserved in freezing medium (10% DMSO in FBS).
Upon thawing, cells were allowed to rest for 6 hr in complete medium before
staining, sorting, and stimulation. Human studies were approved by the
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DC-NK Cell Cocultures
BM-DCs (8 3 104/well) and NK cells (8 3 104/well for IFN-g release assays;
scaling numbers for cytotoxicity assays according to the effector:target ratio)
were cocultured in flat-bottom 96 well plates in the presence or absence of the
following reagents: ultrapure TLR-grade Re-form LPS from E. coli serotype
R515 (1 mg/ml)—shown to be free of any contaminating lipoproteins or pepti-
doglycan, neutralizing anti-IL-1b (B122), anti-IL-1R1 (35F5), anti-IL-18Rb
(TC30-28E3), anti-IL-12(p40/p70) (C17.8), and proper isotype controls from
BD Biosciences; neutralizing anti-IL-18 (D048-3) from MBL International;
neutralizing anti-CD70 (FR70) from eBioscience; neutralizing anti-IL-15
(AF447) and anti-IL-15Ra (AF551) from R&D Systems; recombinant (r) IL-
1RA (1 mg/ml), rIL-18BPd/Fc chimera (1 mg/ml), rhIgG1 Fc (1 mg/ml), rIL-12,
rIL-15, and rIL-18 from R&D Systems; rIFN-b from PBL InterferonSource;
and rIL-2 from Peprotech. All neutralizing Abs and relevant isotype controls
were used at 10 mg/ml and were purchased as no azide/low endotoxin format.
Refer to figure legends for concentrations of recombinant cytokines.
Abs and recombinant proteins aimed at neutralizing cytokines (IL-1RA and
IL-18BPd/Fc chimera) were added 30 min prior to stimulation with LPS. Acti-
vating recombinant cytokines (rIL-2, rIL-18, rIFN-b, and rIL-15) were added
at the time of LPS stimulation.
ELISA
Cell-free supernatants were collected from DC-NK cell cocultures after 18 hr
and were analyzed using an IFN-g DuoSet ELISA Kit (R&D Systems). We
have previously demonstrated that IFN-g is exclusively produced by NK cells
in DC-NK cell cocultures (Granucci et al., 2004).
Immunocytofluorescence
NK cells were cultured in the presence of IFN-b (200 U/ml) for 3 hr before being
cytospun onto glass slides. After fixation with 4% paraformaldehyde and per-
meabilizationwith perm/blocking buffer (0.1%Triton X-100/0.2%BSA in PBS),
cells were stained with a goat anti-mouse IL-15 (10 mg/ml, L-20, Santa Cruz)
followed by a secondary incubation with Alexa Fluor 488-conjugated chicken
anti-goat immunoglobulin G (2 mg/ml, Life Technologies), diluted in blocking
buffer. Cell membranes were counterstained with Alexa Fluor 555-conjugated
Cholera Toxin Subunit B (CTB, Life Technologies). A TCS SP2 confocal micro-
scope (Leica) was used to acquire images. At least five fields were acquired for
each slide.
Quantitative Real-Time PCR
FACS-sorted CD11c+ BM-DCs (from day 10 cultures), ex vivo CD49bhighCD3
murine NK cells (from spleens), or NKp46+CD56+CD3 human NK cells (from
PBMCs) were cultured in the presence of species-matched rIFN-b (200 U/ml)
for the time shown in figures. Cells were lysed with TRIzol (Life Technologies),
and total RNA was extracted with the RNeasy Mini Kit (QIAGEN) according to
themanufacturer’s instructions. A NanoDrop spectrophotometer (Thermo Sci-
entific) was used to quantify RNA and to assess its purity. RNA was retrotran-
scribed to cDNA using the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Then, 10 ng cDNA was amplified using the Power
SYBR Green PCR Master Mix (Applied Biosystems) in a 7500 Fast Real-
Time PCR System (Applied Biosystems), and data were analyzed using the
built-in SDS software.
The sequences of mouse primer pairs were: Il15, 50-CATTTTGGGCTGTGT
CAGTGT-30 and 50-ACTGGGATGAAAGTCACTGTCAGTG-30; Il15ra, 50-GCC
TCAAGTGCATCAGAGACC-30 and 50-ACCTTTGGTGTCACTACTGTTGGC-
30; and 18S, 50-CGAAAGCATTTGCCAAGAAT-30 and 50-AGTCGGCATCGTT
TATGGTC-30. The sequences of human primer pairs were: IL15, 50-TGT
TCCATCATGTTCCATGC-30 and 50-TCCACGATGCCTCCTACAA-30; IL15RA,
50-CAAGCTGTAGCTCTTGACCCA-30 and 50-GCTACTGCTGCTGCTGC
TC-30; and ACTB, 50-GTTGTCGACGACGAGCG-30 and 50-GCACAGAGCC
TCGCCTT-30. 18S and b-actin were used as endogenous references for rela-
tive quantification with the DDCt method.
In Vitro Cytotoxicity Assay
NK cell cytotoxicity was quantitated by a dye-release assay coupled to
time-resolved fluorescence using the DELFIA EuTDA Cytotoxicity Reagents
(PerkinElmer; Blomberg et al., 1996). Briefly, 53 106 YAC-1 target cells resus-1246 Cell Reports 4, 1235–1249, September 26, 2013 ª2013 The Aupended in 1 ml IMDM-10 were labeled with 5 ml BATDA reagent (the acetoxy-
methyl ester of the fluorescence-enhancing organic molecule TDA) at 37C for
30 min. Within cells, the ester bonds are hydrolyzed to form the hydrophilic
TDA, which no longer passes the membrane. Cells were then washed four
times with PBS and 2 3 104 targets per well were added to a 6-hr-long
DC-NK cell coculture for an additional 3 hr. A control of TDA maximal release
was obtained by incubating target cells with DELFIA lysis solution, whereas
spontaneous release was measured on target cells alone. Fifty microliter
cell-free supernatants, containing the TDA released by killed cells, were mixed
to 150 ml DELFIA europium solution and incubated for 10 min with shaking.
Time-resolved fluorescence of the Eu:TDA chelate, correlating with the
number of lysed cells, was measured using a Victor3 plate reader
(PerkinElmer). Medium background was subtracted from all conditions.
Results are shown as the percentage of target cell lysis relative to the
maximum and spontaneous release controls.
In Vivo NK Cell Activation and IFN-g Secretion
To activate NK cells, age-matched mice were injected i.v. with 2 mg LPS/gbw,
except for the experiments depicted in Figure 1, where mice were injected s.c.
in the anterior footpad with 1 mg LPS/gbw. Alternatively, in Figures 3A–3C,
mice were challenged with 3 3 107 E. coli colony-forming units (CFU). Mice
were euthanized 2.5 hr and 4 hr before the 5 hr and 18 hr time points, respec-
tively, to culture RBC-lysed splenocytes in the presence of brefeldin A (BFA;
10 mg/ml; Sigma-Aldrich) for the remaining time. This allowedmeasuring direct
IFN-g release by NK cells in the absence of artificial restimulation. Intracellular
staining was performed using Cytofix/Cytoperm reagents (BD Biosciences)
according to the manufacturer’s instructions, with the following Abs: anti-
CD49b (DX5 or HMa2); anti-CD3ε (145-2C11); anti-CD11c (HL3); and anti-
IFN-g (XMG1.2) (or its isotype control).
Bacterial Challenge
Ampr-E. coli (strain DH5a) was grown to midlogarithmic phase in Luria broth
(LB) medium and frozen at 80C in glycerol stocks. Before infection, E. coli
was regrown in LB/ampicillin medium until optical density 600 = 0.6. Mice
were challenged with 3 3 107 bacteria, as calculated from the linear relation-
ship with turbidity and checked by the number of CFU grown after 24–36 hr at
37C. Spleens were collected and homogenized in 0.2% Triton X-100 18 hr
later. Bacterial titers were determined by serially diluting homogenates on
LB agar plates and counting CFU after 24–36 hr at 37C.
In Vivo Cytotoxicity Assays
Splenocytes isolated from B2 m/ mice were used as NK cell targets in vivo,
whereas theWT counterparts served as a control (Regner et al., 2011). The two
populations were tracked and distinguished upon loading with two different
concentrations (0.75 mMor 0.075 mM) of carboxyfluorescein succinimidyl ester
(CFSE) (Life Technologies). Labeled cells were adoptively transferred at a 1:1
ratio (checked by flow cytometry before injection) along with 2 mg LPS/gbw to
activate NK cells. Target and control cells were recovered 24 hr later from the
spleen, and the ratio between the two populations was assessed by flow
cytometry.
Statistical Analysis
Results are expressed as mean ± SEM from multiple independent experi-
ments. In in vitro studies, n refers to the number of independent experiments.
In in vivo studies, n refers to the number of animals per condition.
Hypotheses were tested with two-tail t tests in single pairwise comparisons
or multiple orthogonal comparisons. ANOVA posthoc tests were used for
correction of multiple nonorthogonal comparisons: Dunnett’s when multiple
conditions were tested against a single control condition; Sidak’s when a sub-
set of conditions was selected for pairwise comparisons; and Tukey’s when all
possible combinations were tested. One-sample two-tail t tests were used for
comparisons against a fixed value (100%). Dependent samples were analyzed
with paired t tests or repeated-measures ANOVA. p values, calculated with
Excel (Microsoft) or Prism (Graphpad), are coded by asterisks: <0.05 (*),
<0.01 (**), <0.001 (***), <0.0001 (****); ns, not significant.
Figure legends report the type of error bars, n, and the hypothesis test used
to compare differences.thors
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2013.08.021.
ACKNOWLEDGMENTS
This work was supported by grants from the European Union FP7
Program (TOLERAGE: HEALTH-F4-2008-202156; ENCITE: HEALTH-F4-
2008-201842), the Associazione Italiana per la Ricerca sul Cancro, the Italian
Ministry of Education and Research (PRIN 2009), the Fondazione Cariplo
(Grant 2010-0678), and Regione Lombardia.
Received: May 31, 2012
Revised: July 12, 2013
Accepted: August 8, 2013
Published: September 19, 2013
REFERENCES
Andrews, D.M., Scalzo, A.A., Yokoyama, W.M., Smyth, M.J., and Degli-Es-
posti, M.A. (2003). Functional interactions between dendritic cells and NK cells
during viral infection. Nat. Immunol. 4, 175–181.
Becker, I., Salaiza, N., Aguirre, M., Delgado, J., Carrillo-Carrasco, N., Kobeh,
L.G., Ruiz, A., Cervantes, R., Torres, A.P., Cabrera, N., et al. (2003). Leishmania
lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol.
Biochem. Parasitol. 130, 65–74.
Berard, M., Brandt, K., Bulfone-Paus, S., and Tough, D.F. (2003). IL-15 pro-
motes the survival of naive and memory phenotype CD8+ T cells.
J. Immunol. 170, 5018–5026.
Beuneu, H., Deguine, J., Breart, B., Mandelboim, O., Di Santo, J.P., and
Bousso, P. (2009). Dynamic behavior of NK cells during activation in lymph
nodes. Blood 114, 3227–3234.
Blomberg, K., Hautala, R., Lo¨vgren, J., Mukkala, V.M., Lindqvist, C., and Aker-
man, K. (1996). Time-resolved fluorometric assay for natural killer activity using
target cells labelled with a fluorescence enhancing ligand. J. Immunol.
Methods 193, 199–206.
Boehm, U., Klamp, T., Groot, M., and Howard, J.C. (1997). Cellular responses
to interferon-gamma. Annu. Rev. Immunol. 15, 749–795.
Brilot, F., Strowig, T., Roberts, S.M., Arrey, F., andMu¨nz, C. (2007). NK cell sur-
vival mediated through the regulatory synapse with human DCs requires IL-
15Ralpha. J. Clin. Invest. 117, 3316–3329.
Burkett, P.R., Koka, R., Chien, M., Chai, S., Boone, D.L., and Ma, A. (2004).
Coordinate expression and trans presentation of interleukin (IL)-15Ralpha
and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis.
J. Exp. Med. 200, 825–834.
Castro, I., Yu, A., Dee, M.J., and Malek, T.R. (2011). The basis of distinctive IL-
2- and IL-15-dependent signaling: weak CD122-dependent signaling favors
CD8+ T central-memory cell survival but not T effector-memory cell develop-
ment. J. Immunol. 187, 5170–5182.
Chaix, J., Tessmer, M.S., Hoebe, K., Fuse´ri, N., Ryffel, B., Dalod, M., Alexo-
poulou, L., Beutler, B., Brossay, L., Vivier, E., and Walzer, T. (2008). Cutting
edge: Priming of NK cells by IL-18. J. Immunol. 181, 1627–1631.
Chalifour, A., Jeannin, P., Gauchat, J.F., Blaecke, A., Malissard, M., N’Guyen,
T., Thieblemont, N., and Delneste, Y. (2004). Direct bacterial protein PAMP
recognition by human NK cells involves TLRs and triggers alpha-defensin pro-
duction. Blood 104, 1778–1783.
Dinarello, C.A. (2009). Immunological and inflammatory functions of the inter-
leukin-1 family. Annu. Rev. Immunol. 27, 519–550.
Dunn, P.L., and North, R.J. (1991). Early gamma interferon production by nat-
ural killer cells is important in defense against murine listeriosis. Infect. Immun.
59, 2892–2900.
Ebihara, T., Azuma, M., Oshiumi, H., Kasamatsu, J., Iwabuchi, K., Matsumoto,
K., Saito, H., Taniguchi, T., Matsumoto, M., and Seya, T. (2010). IdentificationCell Reof a polyI:C-inducible membrane protein that participates in dendritic cell-
mediated natural killer cell activation. J. Exp. Med. 207, 2675–2687.
Fehniger, T.A., Shah, M.H., Turner, M.J., VanDeusen, J.B., Whitman, S.P.,
Cooper, M.A., Suzuki, K., Wechser, M., Goodsaid, F., and Caligiuri, M.A.
(1999). Differential cytokine and chemokine gene expression by human NK
cells following activation with IL-18 or IL-15 in combination with IL-12: implica-
tions for the innate immune response. J. Immunol. 162, 4511–4520.
Ferlazzo, G., Tsang, M.L., Moretta, L., Melioli, G., Steinman, R.M., and Mu¨nz,
C. (2002). Human dendritic cells activate resting natural killer (NK) cells and are
recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195,
343–351.
Ferlazzo, G., Morandi, B., D’Agostino, A., Meazza, R., Melioli, G., Moretta, A.,
and Moretta, L. (2003). The interaction between NK cells and dendritic cells in
bacterial infections results in rapid induction of NK cell activation and in the
lysis of uninfected dendritic cells. Eur. J. Immunol. 33, 306–313.
Ferlazzo, G., Pack, M., Thomas, D., Paludan, C., Schmid, D., Strowig, T.,
Bougras, G., Muller, W.A., Moretta, L., and Mu¨nz, C. (2004). Distinct roles of
IL-12 and IL-15 in human natural killer cell activation by dendritic cells from
secondary lymphoid organs. Proc. Natl. Acad. Sci. USA 101, 16606–16611.
Fernandez, N.C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D.,
Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., and Zitvogel, L.
(1999). Dendritic cells directly trigger NK cell functions: cross-talk relevant in
innate anti-tumor immune responses in vivo. Nat. Med. 5, 405–411.
Fink, L.N., Zeuthen, L.H., Christensen, H.R., Morandi, B., Frøkiaer, H., and Fer-
lazzo, G. (2007). Distinct gut-derived lactic acid bacteria elicit divergent den-
dritic cell-mediated NK cell responses. Int. Immunol. 19, 1319–1327.
French, A.R., and Yokoyama, W.M. (2003). Natural killer cells and viral infec-
tions. Curr. Opin. Immunol. 15, 45–51.
French, A.R., Sjo¨lin, H., Kim, S., Koka, R., Yang, L., Young, D.A., Cerboni, C.,
Tomasello, E., Ma, A., Vivier, E., et al. (2006). DAP12 signaling directly aug-
ments proproliferative cytokine stimulation of NK cells during viral infections.
J. Immunol. 177, 4981–4990.
Gorski, K.S., Waller, E.L., Bjornton-Severson, J., Hanten, J.A., Riter, C.L.,
Kieper, W.C., Gorden, K.B., Miller, J.S., Vasilakos, J.P., Tomai, M.A., and
Alkan, S.S. (2006). Distinct indirect pathways govern human NK-cell activation
by TLR-7 and TLR-8 agonists. Int. Immunol. 18, 1115–1126.
Granucci, F., Vizzardelli, C., Pavelka, N., Feau, S., Persico, M., Virzi, E., Re-
scigno, M., Moro, G., and Ricciardi-Castagnoli, P. (2001). Inducible IL-2 pro-
duction by dendritic cells revealed by global gene expression analysis. Nat.
Immunol. 2, 882–888.
Granucci, F., Zanoni, I., Pavelka, N., Van Dommelen, S.L., Andoniou, C.E., Be-
lardelli, F., Degli Esposti, M.A., and Ricciardi-Castagnoli, P. (2004). A contribu-
tion of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med.
200, 287–295.
Hart, O.M., Athie-Morales, V., O’Connor, G.M., and Gardiner, C.M. (2005).
TLR7/8-mediated activation of human NK cells results in accessory cell-
dependent IFN-gamma production. J. Immunol. 175, 1636–1642.
Hochweller, K., Striegler, J., Ha¨mmerling, G.J., and Garbi, N. (2008). A novel
CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their
requirement for homeostatic proliferation of natural killer cells. Eur. J. Immunol.
38, 2776–2783.
Horowitz, A., Stegmann, K.A., and Riley, E.M. (2012). Activation of natural killer
cells during microbial infections. Front. Immunol. 2, 88.
Huntington, N.D., Legrand, N., Alves, N.L., Jaron, B., Weijer, K., Plet, A., Cor-
cuff, E., Mortier, E., Jacques, Y., Spits, H., and Di Santo, J.P. (2009). IL-15
trans-presentation promotes human NK cell development and differentiation
in vivo. J. Exp. Med. 206, 25–34.
Ikawa, M., Yamada, S., Nakanishi, T., and Okabe, M. (1998). ‘Green mice’ and
their potential usage in biological research. FEBS Lett. 430, 83–87.
Ikemizu, S., Chirifu, M., and Davis, S.J. (2012). IL-2 and IL-15 signaling com-
plexes: different but the same. Nat. Immunol. 13, 1141–1142.
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu,
S., and Steinman, R.M. (1992). Generation of large numbers of dendritic cellsports 4, 1235–1249, September 26, 2013 ª2013 The Authors 1247
from mouse bone marrow cultures supplemented with granulocyte/macro-
phage colony-stimulating factor. J. Exp. Med. 176, 1693–1702.
Jung, S., Unutmaz, D., Wong, P., Sano, G., De los Santos, K., Sparwasser, T.,
Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002). In vivo depletion of CD11c+
dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associ-
ated antigens. Immunity 17, 211–220.
Koka, R., Burkett, P., Chien, M., Chai, S., Boone, D.L., and Ma, A. (2004). Cut-
ting edge: murine dendritic cells require IL-15R alpha to prime NK cells.
J. Immunol. 173, 3594–3598.
Lanier, L.L. (2005). NK cell recognition. Annu. Rev. Immunol. 23, 225–274.
Lapaque, N., Walzer, T., Me´resse, S., Vivier, E., and Trowsdale, J. (2009).
Interactions between humanNK cells andmacrophages in response to Salmo-
nella infection. J. Immunol. 182, 4339–4348.
Lauzon, N.M., Mian, F., MacKenzie, R., and Ashkar, A.A. (2006). The direct
effects of Toll-like receptor ligands on human NK cell cytokine production
and cytotoxicity. Cell. Immunol. 241, 102–112.
Lauzon, N.M., Mian, F., and Ashkar, A.A. (2007). Toll-like receptors, natural
killer cells and innate immunity. Adv. Exp. Med. Biol. 598, 1–11.
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., and Diefenbach, A. (2007).
Dendritic cells prime natural killer cells by trans-presenting interleukin 15.
Immunity 26, 503–517.
Ma, A., Koka, R., andBurkett, P. (2006). Diverse functions of IL-2, IL-15, and IL-
7 in lymphoid homeostasis. Annu. Rev. Immunol. 24, 657–679.
Martı´n-Fontecha, A., Thomsen, L.L., Brett, S., Gerard, C., Lipp, M., Lanzavec-
chia, A., and Sallusto, F. (2004). Induced recruitment of NK cells to lymph
nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5, 1260–1265.
McCartney, S., Vermi, W., Gilfillan, S., Cella, M., Murphy, T.L., Schreiber, R.D.,
Murphy, K.M., and Colonna, M. (2009). Distinct and complementary functions
of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J. Exp.
Med. 206, 2967–2976.
Medzhitov, R., Preston-Hurlburt, P., and Janeway, C.A., Jr. (1997). A human
homologue of the Drosophila Toll protein signals activation of adaptive immu-
nity. Nature 388, 394–397.
Miyake, T., Kumagai, Y., Kato, H., Guo, Z., Matsushita, K., Satoh, T., Kawagoe,
T., Kumar, H., Jang, M.H., Kawai, T., et al. (2009). Poly I:C-induced activation
of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent
pathways. J. Immunol. 183, 2522–2528.
Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M.C., and
Moretta, A. (2006). Effector and regulatory events during natural killer-dendritic
cell interactions. Immunol. Rev. 214, 219–228.
Mortier, E., Woo, T., Advincula, R., Gozalo, S., and Ma, A. (2008). IL-15Ralpha
chaperones IL-15 to stable dendritic cell membrane complexes that activate
NK cells via trans presentation. J. Exp. Med. 205, 1213–1225.
Muntasell, A., Magri, G., Pende, D., Angulo, A., and Lo´pez-Botet, M. (2010).
Inhibition of NKG2D expression in NK cells by cytokines secreted in response
to human cytomegalovirus infection. Blood 115, 5170–5179.
Murphy, W.J., Parham, P., and Miller, J.S. (2012). NK cells—from bench to
clinic. Biol. Blood Marrow Transplant. 18(Suppl), S2–S7.
Netea, M.G., Nold-Petry, C.A., Nold, M.F., Joosten, L.A., Opitz, B., van der
Meer, J.H., van de Veerdonk, F.L., Ferwerda, G., Heinhuis, B., Devesa, I.,
et al. (2009). Differential requirement for the activation of the inflammasome
for processing and release of IL-1beta in monocytes and macrophages. Blood
113, 2324–2335.
Newman, K.C., and Riley, E.M. (2007). Whatever turns you on: accessory-
cell-dependent activation of NK cells by pathogens. Nat. Rev. Immunol. 7,
279–291.
Nguyen, K.B., Cousens, L.P., Doughty, L.A., Pien, G.C., Durbin, J.E., and
Biron, C.A. (2000). Interferon alpha/beta-mediated inhibition and promotion
of interferon gamma: STAT1 resolves a paradox. Nat. Immunol. 1, 70–76.
Nguyen, K.B., Salazar-Mather, T.P., Dalod, M.Y., Van Deusen, J.B., Wei, X.Q.,
Liew, F.Y., Caligiuri, M.A., Durbin, J.E., and Biron, C.A. (2002). Coordinated1248 Cell Reports 4, 1235–1249, September 26, 2013 ª2013 The Auand distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell
responses to viral infection. J. Immunol. 169, 4279–4287.
Olsen, S.K., Ota, N., Kishishita, S., Kukimoto-Niino, M., Murayama, K.,
Uchiyama, H., Toyama, M., Terada, T., Shirouzu, M., Kanagawa, O., and
Yokoyama, S. (2007). Crystal Structure of the interleukin-15.interleukin-15
receptor alpha complex: insights into trans and cis presentation. J. Biol.
Chem. 282, 37191–37204.
Orange, J.S., and Biron, C.A. (1996). An absolute and restricted requirement
for IL-12 in natural killer cell IFN-gamma production and antiviral defense.
Studies of natural killer and T cell responses in contrasting viral infections.
J. Immunol. 156, 1138–1142.
Pisegna, S., Pirozzi, G., Piccoli, M., Frati, L., Santoni, A., and Palmieri, G.
(2004). p38 MAPK activation controls the TLR3-mediated up-regulation of
cytotoxicity and cytokine production in human NK cells. Blood 104, 4157–
4164.
Pohl, T., Krause, H., Du¨rkop, H., Paus, R., and Bulfone-Paus, S. (2011). Retrac-
tion: The IL-15Ra chain signals through association with Syk in human B cells.
J. Immunol. 186, 2681.
Poltorak, A., He, X., Smirnova, I., Liu, M.Y., Van Huffel, C., Du, X., Birdwell, D.,
Alejos, E., Silva, M., Galanos, C., et al. (1998). Defective LPS signaling in C3H/
HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085–
2088.
Pontiroli, F., Dussurget, O., Zanoni, I., Urbano, M., Beretta, O., Granucci,
F., Ricciardi-Castagnoli, P., Cossart, P., and Foti, M. (2012). The timing
of IFNb production affects early innate responses to Listeria monocyto-
genes and determines the overall outcome of lethal infection. PLoS ONE
7, e43455.
Ranson, T., Vosshenrich, C.A., Corcuff, E., Richard, O., Mu¨ller, W., and Di
Santo, J.P. (2003). IL-15 is an essential mediator of peripheral NK-cell homeo-
stasis. Blood 101, 4887–4893.
Regner, M., Pavlinovic, L., Young, N., and Mu¨llbacher, A. (2011). In vivo elim-
ination of MHC-I-deficient lymphocytes by activated natural killer cells is inde-
pendent of granzymes A and B. PLoS ONE 6, e23252.
Ring, A.M., Lin, J.X., Feng, D., Mitra, S., Rickert, M., Bowman, G.R., Pande,
V.S., Li, P., Moraga, I., Spolski, R., et al. (2012). Mechanistic and structural
insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol.
13, 1187–1195.
Robinson, D., Shibuya, K., Mui, A., Zonin, F., Murphy, E., Sana, T., Hartley,
S.B., Menon, S., Kastelein, R., Bazan, F., and O’Garra, A. (1997). IGIF does
not drive Th1 development but synergizes with IL-12 for interferon-gamma
production and activates IRAK and NFkappaB. Immunity 7, 571–581.
Romo, N.,Magri, G., Muntasell, A., Heredia, G., Baı´a, D., Angulo, A., Guma,M.,
and Lo´pez-Botet, M. (2011). Natural killer cell-mediated response to human
cytomegalovirus-infected macrophages is modulated by their functional
polarization. J. Leukoc. Biol. 90, 717–726.
Rowley, J., Monie, A., Hung, C.F., and Wu, T.C. (2009). Expression of IL-15RA
or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred
T-cell function in cis. Eur. J. Immunol. 39, 491–506.
Schmidt, K.N., Leung, B., Kwong, M., Zarember, K.A., Satyal, S., Navas, T.A.,
Wang, F., and Godowski, P.J. (2004). APC-independent activation of NK cells
by the Toll-like receptor 3 agonist double-stranded RNA. J. Immunol. 172,
138–143.
Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821–832.
Sen, G.C. (2001). Viruses and interferons. Annu. Rev. Microbiol. 55, 255–281.
Sivori, S., Falco, M., Della Chiesa, M., Carlomagno, S., Vitale, M., Moretta, L.,
and Moretta, A. (2004). CpG and double-stranded RNA trigger human NK
cells by Toll-like receptors: induction of cytokine release and cytotoxicity
against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA 101, 10116–
10121.
Sivori, S., Carlomagno, S., Moretta, L., and Moretta, A. (2006). Comparison of
different CpG oligodeoxynucleotide classes for their capability to stimulate
human NK cells. Eur. J. Immunol. 36, 961–967.thors
Sivori, S., Falco, M., Carlomagno, S., Romeo, E., Moretta, L., and Moretta, A.
(2007). Heterogeneity of TLR3 mRNA transcripts and responsiveness to poly
(I:C) in human NK cells derived from different donors. Int. Immunol. 19,
1341–1348.
Sun, J.C., Ma, A., and Lanier, L.L. (2009). Cutting edge: IL-15-independent NK
cell response to mouse cytomegalovirus infection. J. Immunol. 183, 2911–
2914.
Takeda, K., Oshima, H., Hayakawa, Y., Akiba, H., Atsuta, M., Kobata, T.,
Kobayashi, K., Ito, M., Yagita, H., and Okumura, K. (2000). CD27-mediated
activation of murine NK cells. J. Immunol. 164, 1741–1745.
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T.,
Takeda, K., and Akira, S. (1999). Differential roles of TLR2 and TLR4 in recog-
nition of gram-negative and gram-positive bacterial cell wall components.
Immunity 11, 443–451.
Tsujimoto, H., Uchida, T., Efron, P.A., Scumpia, P.O., Verma, A., Matsumoto,
T., Tschoeke, S.K., Ungaro, R.F., Ono, S., Seki, S., et al. (2005). Flagellin
enhances NK cell proliferation and activation directly and through dendritic
cell-NK cell interactions. J. Leukoc. Biol. 78, 888–897.
Walzer, T., Ble´ry, M., Chaix, J., Fuseri, N., Chasson, L., Robbins, S.H., Jaeger,
S., Andre´, P., Gauthier, L., Daniel, L., et al. (2007). Identification, activation, andCell Reselective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci.
USA 104, 3384–3389.
Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and
Akira, S. (2002). Cutting edge: a novel Toll/IL-1 receptor domain-containing
adapter that preferentially activates the IFN-beta promoter in the Toll-like
receptor signaling. J. Immunol. 169, 6668–6672.
Zanoni, I., Foti, M., Ricciardi-Castagnoli, P., and Granucci, F. (2005). TLR-
dependent activation stimuli associated with Th1 responses confer NK cell
stimulatory capacity to mouse dendritic cells. J. Immunol. 175, 286–292.
Zanoni, I., Ostuni, R., Marek, L.R., Barresi, S., Barbalat, R., Barton, G.M., Gran-
ucci, F., and Kagan, J.C. (2011). CD14 controls the LPS-induced endocytosis
of Toll-like receptor 4. Cell 147, 868–880.
Zanoni, I., Bodio, C., Broggi, A., Ostuni, R., Caccia, M., Collini, M., Venkatesh,
A., Spreafico, R., Capuano, G., and Granucci, F. (2012). Similarities and differ-
ences of innate immune responses elicited by smooth and rough LPS. Immu-
nol. Lett. 142, 41–47.
Zhang, X., Sun, S., Hwang, I., Tough, D.F., and Sprent, J. (1998). Potent and
selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15.
Immunity 8, 591–599.ports 4, 1235–1249, September 26, 2013 ª2013 The Authors 1249
